Bernstein said Novo Nordisk’s (NVO) recently released SOUL study results for Rybelsus in the reduction of major cardiovascular events in diabetic patients were modest and not as robust as ...

Later-to-market Ozempic is lagging behind Trulicity, with first-half sales of around $550 million, but has been predicted to reach $2 to $3 billion per year at peak, with Rybelsus having the ...

Rybelsus is an oral form of semaglutide, the active ingredient in the company’s blockbuster Ozempic and Wegovy diabetes and weight-loss drugs, and was tested in the trial on diabetic patients ...

Novo Nordisk's GLP-1 medication, Rybelsus, reduced major adverse cardiovascular events by 14% compared to a placebo in a phase 3 trial, the drugmaker said Oct. 21. Rybelsus, a daily pill approved ...

On October 21, Novo Nordisk announced positive news on the cardiovascular benefits of its oral glucagon-like peptide-1 receptor (GLP-1R) agonist, Rybelsus, which is currently approved for type 2 ...

Initially approved by the FDA in 2019 as the first oral GLP-1 med, Rybelsus generated first-half 2024 sales of 10.9 billion Danish kroner ($1.6 billion). That compared with Ozempic's 56.7 billion ...

Rybelsus (semaglutide) is the first GLP-1 agonist drug that can be dosed orally, and is Novo Nordisk's third drug in the class after daily injectable Victoza (liraglutide) and weekly shot Ozempic ...

The study showed that Rybelsus, the company's oral form of semaglutide ... it lowered the odds of life-threatening events like heart attacks and strokes. This positions Novo Nordisk to redefine ...

Oral semaglutide (Rybelsus) lowered the risk for major adverse ... and established cardiovascular disease and/or chronic kidney disease. About half of the participants also received sodium-glucose ...

Bernstein said Novo Nordisk’s (NVO) recently released SOUL study results for Rybelsus in the reduction of major cardiovascular events in diabetic patients were modest and not as robust as ...